Cvd definitions and statistics jan 2012

Cardiovascular Epidemiology
and Prevention
Nathan D. Wong, PhD, FACC, FAHA
Professor and Director, Heart Disease
Prevention Program, Division of
Cardiology, University of California, Irvine
President, American Society of Preventive
Cardiology

Cardiovascular Epidemiology:
Definitions, Concepts,
Historical Perspectives and
Statistics

Definitions
• CORONARY ARTERY DISEASE (CAD) or
CORONARY HEART DISEASE (CHD) (often
broadly referred to as ISCHEMIC HEART
DISEASE (IHD): primarily myocardial
infarction and sudden coronary death,
broader definition may include angina
pectoris, atherosclerosis, positive
angiogram, and revascularization
(perceutaneous coronary interventions, or
PCI such as angioplasty and stents)

• CARDIOVASCULAR DISEASE or CVD
includes CHD, cerebrovascular disease,
peripheral vascular disease, and other
cardiac conditions (congenital,
arrhythmias, and congestive heart failure)

Definitions (cont.)
• SURROGATE MEASURES include: carotid
intimal medial thickness (IMT), coronary
calcium, angiographic stenosis, brachial
ultrasound flow mediated dilatation (FMD)

• Hard endpoints include myocardial
infarction, CHD death, and stroke

CVD and other major causes of death for all males and females
(United States: 2007).

Source: NCHS and NHLBI. A indicates CVD plus congenital CVD; B, cancer; C, accidents; D, CLRD; E, diabetes; and F, Alzheimer's disease.

©2010 American Heart Association, Inc. All rights reserved. Roger VL et al. Published online in Circulation Dec. 15, 2010

Trends in cardiovascular procedures, United States: 1979–2009

Note: Inpatient procedures only. Source: National Hospital Discharge Survey, NCHS, and NHLBI.

Direct and indirect costs (in billions of dollars)
of major cardiovascular diseases and stroke (United States: 2008)

Source: National Heart, Lung, and Blood Institute.

Projected Total Costs of CVD, 2015–2030 (in Billions 2008$) in the United States

Unpublished data tabulated by AHA using methods described in Circulation. 2011;123:933–944.


550
Deaths in Thousands

500

450

400

350
79 80 85 90 95 00 06
Years

Males Females

CVD disease mortality trends for males and females
(United States: 1979-2006).
Source: NCHS and NHLBI.

7

6
Discharges in Millions

5

4

3

2

1

0
70 75 80 85 90 95 00 06
Years

Hospital discharges for cardiovascular diseases.
(United States: 1970-2006). Note: Hospital discharges include
people discharged alive, dead and status unknown.

Prevalence of CVD in adults ≥20 years of age by age and sex (NHANES: 2005–2008)

Source: NCHS and NHLBI. These data include CHD, HF, stroke, and hypertension.

Deaths due to diseases of the heart (United States: 1900–2008)

Source: National Center for Health Statistics.


1,000
831
Deaths in Thousands

800

600 560

400 315
242
138 165
200 81 101 120 85
25 21 48 50
0
<45 45-54 55-64 65-74 75-84 85+ Total
Ages

CVD Cancer

CVD deaths vs. cancer deaths by age.
(United States: 2006). Source: NCHS.

CVD and other major causes of death for all males and females (United States: 2008)

Source: NCHS and NHLBI. A indicates CVD plus congenital CVD; B, cancer; C, accidents; D, CLRD; E, diabetes; and F, Alzheimer's disease.


Prevalence of stroke by age and sex (NHANES: 2005–2008)



Prevalence of stroke by age and sex (NHANES: 2005–2008).



Coronary Heart
Disease
Stroke
14
4
7 HF*

51 High Blood Pressure
7
17 Diseases of the
Arteries
Other

Percentage breakdown of deaths from cardiovascular diseases
(United States: 2006) * - Not a true underlying cause.
Source: NCHS.

16
13.8
14 12.2
Percent of Population

12
9.3
10
8
6 4.8
4 2.2
2 1.2
0.1 0.2
0
20-39 40-59 60-79 80+

Men Women

Prevalence of heart failure by age and sex
(NHANES: 2005-2006). Source: NCHS and NHLBI.

700
Discharges in Thousands

600
500
400

300
200
100
0
79 80 85 90 95 00 06
Years

Male Female

Hospital discharges for heart failure by sex.
(United States: 1979-2006). Source: NHDS/NCHS and NHLBI.
Note: Hospital discharges include people discharged alive, dead
and status unknown.

Development of Atherosclerotic
Plaques
Fatty streak
Normal

Lipid-rich plaque

Foam cells

Fibrous cap

Lipid core
Thrombus

Ross R. Nature. 1993;362:801-809.

PDAY: Percentage of Right Coronary Artery
Intimal Surface Affected With Early Atherosclerosis

30 Raised lesions 30
Men Fatty streaks
Women

20 20

10 10

0 0
Intimal 15-19 20-24 25-29 30-34 15-19 20-24 25-29 30-34
surface 30 White White
30
(%)
20 20

10 10

0 0
15-19 20-24 25-29 30-34 15-1920-2425-2930-34
Black Black

Age (y)
PDAY= Pathobiological Determinants of Atherosclerosis in Youth.
Strong JP, et al. JAMA. 1999;281:727-735.

Most Myocardial Infarctions Are Caused
by Low-Grade Stenoses

Pooled data from 4 studies: Ambrose et al, 1988; Little et al, 1988; Nobuyoshi et al, 1991; and Giroud et al,
1992.
(Adapted from Falk et al.)
Falk E et al, Circulation, 1995.

Coronary Remodeling

Progression
Expansion
Compensatory expansion overcome:
maintains constant lumen lumen narrows

Normal Minimal Moderate Severe
vessel CAD CAD CAD
(Adapted from Glagov et al.)

Glagov et al, N Engl J Med, 1987.
Med,

Atherosclerotic Plaque Rupture and
Thrombus Formation

Growth of thrombus
Intraluminal thrombus

Blood Flow

Intraplaque thrombus Lipid pool

Adapted from Weissberg PL. Eur Heart J Supplements
1999:1:T13–18

Features of a Ruptured
Atherosclerotic Plaque

• Eccentric, lipid-rich
• Fragile fibrous cap
• Prior luminal
obstruction < 50%
• Visible rupture
and thrombus

Constantinides P. Am J Cardiol. 1990;66:37G-40G.

Vulnerable Versus Stable
Atherosclerotic Plaques
Vulnerable Plaque
Lumen Lipid •Thin fibrous cap
Fibrous Cap
Core •Inflammatory cell infiltrates:
proteolytic activity
•Lipid-rich plaque

Stable Plaque
•Thick fibrous cap
Lumen Lipid •Smooth muscle cells:
Core
more extracellular matrix
Fibrous Cap
•Lipid-poor plaque

Libby P. Circulation. 1995;91:2844-2850.

Correlation of CT angiography of the
coronary arteries with intravascular
ultrasound illustrates the ability of MDCT
to demonstrate calcified and non-calcified
coronary plaques (Becker et al., Eur J
Radiol 2000) Non-calcified, soft, lipid-rich plaque in
left anterior descending artery (arrow)
(Somatom Sensation 4, 120 ml Imeron
400). The plaque was confirmed by
intravascular ultrasound (Kopp et al.,
Radiology 2004)

Concept of cardiovascular
“risk factors”

Age, sex, hypertension, hyperlipidemia, smoking, diabetes,
(family history), (obesity)

Kannel et al, Ann Intern Med 1961

Major Risk Factors
• Cigarette smoking (passive smoking?)
• Elevated total or LDL-cholesterol
• Hypertension (BP ≥ 140/90 mmHg or on
antihypertensive medication)
• Low HDL cholesterol (<40 mg/dL)†
• Family history of premature CHD
– CHD in male first degree relative <55
years
– CHD in female first degree relative <65
years
• Age (men ≥ 45 years; women ≥ 55 years)

†
HDL cholesterol ≥60 mg/dL counts as a “negative” risk factor; its
presence removes one risk factor from the total count.

Other Recognized Risk
Factors
• Obesity: Body Mass Index (BMI)
– Weight (kg)/height (m2)
– Weight (lb)/height (in2) x 703
• Obesity BMI >30 kg/m2 with overweight
defined as 25-<30 kg/m 2
• Abdominal obesity involves waist
circumference >40 in. in men, >35 in. in
women
• Physical inactivity: most experts
recommend at least 30 minutes moderate
activity at least 4-5 days/week

Prevalence (unadjusted) estimates for poor, intermediate and ideal cardiovascular health
for each of the 7 metrics of cardiovascular health in the AHA 2020 goals,
US children aged 12-19 years, NHANES 2007-2008


Age-standardized prevalence for poor, intermediate and ideal cardiovascular health for each
of the 7 metrics of cardiovascular health in the AHA 2020 goals,
among US adults >20 years of age, NHANES 2007-2008


___________________________________________________________
_
Lifetime Risk of Coronary Heart Disease
in the Framingham Study
______________________________________________________________

Men Women
At age 40 years: 48.6% 31.7%
At age 70 years: 34.9% 24.2%
_________________________________________________________________
Lloyd-Jones et al. Lancet 1999; 353:89-92

____________________________________________________________

First Coronary Events: Framingham
Study
________________________________________________________

Percent as Specified Event
Myocardial Angina Sudden
Infarction Pectoris Death
Age Men Women Men Women Men Women
35-64 43% 28% 41% 59% 9% 4%
65-84 55% 44% 28% 41% 11% 7.4%

____________________________________________________________
Framingham Study 44 year follow-up.

Estimated 10-Year CHD Risk in
55-Year-Old Adults According to Levels
of Various Risk Factors
Framingham Heart Study

A B C D
Blood Pressure (mm Hg) 120/80 140/90 140/90 140/90
Total Cholesterol (mg/dL) 200 240 240 240
HDL Cholesterol (mg/dL) 50 50 40 40
Diabetes No No Yes Yes
Cigarettes No No No Yes
mm Hg = millimeters of mercury
mg/dL = milligrams per deciliter of blood

Source: Circulation 1998;97:1837-1847.

Estimated 10-Year Stroke Risk in 55-
Year-Old Adults According to Levels of
Various Risk Factors
Estimated 10-Year Rate (%)

Framingham Heart Study
30 27
25 22.4
19.1
20
14.8
15

10 8.4
5.4 6.3
5 4 3.5
2.6 2
1.1
0

A B C D E F
Men Women

A B C D E F
Systolic BP* 95-105 130-148 130-148 130-148 130-148 130-148
Diabetes No No Yes Yes Yes Yes
Cigarettes No No No Yes Yes Yes
Prior Atrial Fib. No No No No Yes Yes
Prior CVD No No No No No Yes

Source: Stroke 1991;22:312-318. *BP in millimeters of mercury (mmHg)

Offspring CVD Risk by Parental CVD Status:
Framingham Study
Parental CVD <55
Risk Ratio men, <65 Women
2.5
2.5 NONE
MATERNAL
2
2 PATERNAL
2.2
1.5
1.7 1.7 1.7
1
1
1.0 1.0
0.5
0.5

0
0
Men
MEN Women
WOMEN
Adjusted for: age, total/HDL Chol. ratio, SBP, smoking, diabetes, BMI

Risk imposed by a strong family
history of heart attacks varies widely
depending on the burden of
modifiable risk factors

Multivariable Risk

9

Doubts about
cholesterol as
late as 1989

_______________________________________________________________________________

Lifetime Risk of CHD Increases with Serum
Cholesterol
___________________________________________________________________________

60
Cholesterol
50 57 <200 mg
200-239 mg
>240 mg
40
44
Percent

30 34
33
20 29

19
10

0
Men Women
Framingham Study: Subjects age 40 years
DM Lloyd-Jones et al Arch Intern Med 2003; 1966-1972

Correlation Between Serum
Cholesterol and CVD Mortality
Multiple Risk Factor Intervention Trial (MRFIT)
30
N=325,346
Untreated Patients
6-Year CVD Death Rate Per 1000

25 55-57 years

20 50-54 years

15
45-49 years
10
40-44 years

5 35-39 years

0
Q1 Q2 Q3 Q4 Q5
(<182) (182-202) (203-220) (221-244) (>244)
Serum Cholesterol Quintile (mg/dL)
Q = serum cholesterol quintile.
Kannel WB et al. Am Heart J. 1986;112:825-836.

Trends in mean total serum cholesterol among adolescents 12–17 years of
age by race, sex, and survey year (NHANES: 1988–1994*, 1999–2004 and
2005-2008).

Source: NCHS and NHLBI. NH indicates non-Hispanic. Mex. Am. indicates Mexican American.
* Data for Mexican Americans not available.

Trends in mean total serum cholesterol among adults ages ≥20
by race and survey year,
(NHANES: 1988–1994, 1999–2004 and 2005–2008).

Source: NCHS and NHLBI. NH indicates non-Hispanic.


________________________________________________________

CK Friedberg on Hypertension:
___________________________________________________________
Diseases of the Heart 1996

“There is a lack of correlation in
most cases between the severity
and duration of hypertension and
development of cardiac
complications.”
______________________________________________________________
_

Relation of Non-Hypertensive Blood
Pressure to Cardiovascular Disease
Vasan R, et al. N Engl J Med 2001; 345:1291-1297

10-year Age- Adjusted Cumulative Incidence
12% Hazard Ratio*
<120/80 mm Hg
120-129/80-84 mm Hg SBP Women Men
10%
130-139/85-89 mm Hg 10.1
<120/80 1.0 1.0
8% 120-129 1.5 1.3
7.6 130-139 2.5 1.6
6%
5.8 H.R. adjusted for age, BMI,
4% Cholesterol, Diabetes and
4.4
smoking *P<.001
2.8
2%
1.9
0%
Women Men
Framingham Study: Subjects Ages 35-90 yrs.

Prevalence of High Blood Pressure in adults ≥20 years of age
by age and sex (NHANES: 2005–2008)

Source: NCHS and NHLBI. Hypertension is defined as SBP 140 mm Hg or DBP 90 mmHg, taking antihypertensive medication, or being told twice by a
physician or other professional that one has hypertension.

90 82.3
78.8 79.0
Percent of Population With

80 69.1 70.1
74.7
67.6
70
Hypertension

60 52.1
46.5
50 45.4 46.1
40 35.2

30
20
10
0
Awareness Treatment Controlled

Total Population NH Whites NH Blacks Mexican Americans

Extent of awareness, treatment and control of high blood
pressure by race/ethnicity (NHANES : 2005-2006).

______________________________________________________________
_

CK Friedberg on Hypertension
______________________________________________________________
Diseases of the Heart 1966 _

“Hypertension imposes a load on
the heart which for many years
may be compensated by left
ventricular hypertrophy”

______________________________________________________________
CVD Risk Imposed by ECG-LVH _

Framingham Study 36-yr. Follow-up
_______________________________________________________________
Age-adjusted Risk Excess Risk
Rate per 1000 Ratio per 1000
Age Men Women Men Women Men Women
35-64 164 135 4.7*** 7.4*** 129 117
65-94 234 235 2.8*** 4.1*** 51 178
_____________________________________________________________
Biennial Rate per 1000. CVD=CHD, stroke,
peripheral vascular disease, heart failure
***P<0.001

___________________________________________________________
_
Smoking Statement Issued in 1956 by
American Heart Association
___________________________________________________________
“It is the belief of the committee that much
greater knowledge is needed before
any conclusions can be drawn
concerning relationships between
smoking and death rates from coronary
heart disease. The acquisition of such
knowledge may well require the use of
techniques and research methods that
have not hitherto been applied to this
__________________________________________________________
problem.” _

CHD Risk by Cigarette Smoking. Filter
Vs. Non-filter. Framingham Study. Men
<55 Yrs.
14-yr.
Rate/1000
250
Non-Smoker
200 Reg. Cig. Smoker
206
210 Filter Cig. Smoker
150

210
100 119
112

50 59

0
Total CHD Myocardial
Infarction

Prevalence of students in grades 9 to 12 reporting current cigarette use
by sex and race/ethnicity (YRBSS, 2009)

Source: MMWR Surveill Summ. 2010;59:1–142.NH indicates non-Hispanic.


Prevalence of current smoking for adults > 18 years of age
by race/ethnicity and sex (NHIS: 2007-2009)

All percentages are age-adjusted. NH indicates non-Hispanic. *Includes both Hispanics and non-Hispanics. Data derived from Centers for Disease Control
and Prevention/National Center for Health Statistics, Health Data Interactive.


Prevalence of current smoking for adults > 18 years of age
by race/ethnicity and sex (NHIS: 2006-2008)

Source: CDC/NCHS, Health Data Interactive. All percentages are age-adjusted. NH indicates non-Hispanic.
* Includes both Hispanics and non-Hispanics.

Diseases of The Heart
Charles K Friedberg MD, WB
Saunders Co. Philadelphia, 1949
________________________________________________________________

“The proper control of diabetes is
obviously desirable even though
there is uncertainty as to whether
coronary atherosclerosis is more
frequent or severe in the
uncontrolled diabetic”
______________________________________________________________

Risk of Cardiovascular Events in Diabetics
Framingham Study
________________________________________________________________
_
Age-adjusted
Biennial Rate Age-adjusted
Per 1000 Risk Ratio
Cardiovascular Event Men Women Men Women
Coronary Disease 39 21 1.5** 2.2***
Stroke 15 6 2.9*** 2.6***
Peripheral Artery Dis. 18 18 3.4*** 6.4***
Cardiac Failure 23 21 4.4*** 7.8***
All CVD Events 76 65 2.2*** 3.7***
________________________________________________________________
Subjects 35-64 36-year Follow-up **P<.001,***P<.0001
_

Age-adjusted prevalence of physician-diagnosed diabetes in
adults ≥20 years of age
by race/ethnicity and sex (NHANES: 2005–2008).

Source: NCHS and NHLBI. NH indicates non-Hispanic.


Trends in diabetes prevalence in adults ≥20 years of age, by
sex
(NHANES: 1988–1994 and 2005–2008).

Source: NCHS, NHLBI.


Skepticism About Importance of Obesity
Keys A, Aravanis C, Blackburn H, et al. Ann Intern Med
1972; 77:15-27.
Concluded that all the excess risk of coronary heart
disease in the obese derives from its atherogenic
accompaniments, illogically leaving the impression that obesity
is therefore unimportant.
Mann GV. N Engl J Med 1974; 291:226-232.
“The contribution of obesity to CHD is either small or
non-existent. It cannot be expected that treating obesity is
either logical or a promising approach to the management of
CHD”.
Barrett-Connor EL. Ann Intern Med 1985; 103:1010-1019
NIH consensus panel is equivocal about the role of
obesity as a cause of CHD.

Relation of Weight Change to Changes in
Atherogenic Traits: The Framingham Study
Frantz Ashley, Jr. and William B Kannel
J Chronic Dis 1974
“Weight gain is accompanied by atherogenic alterations in
blood lipids, blood pressure, uric acid and carbohydrate
tolerance.”
“It seems reasonable to expect that correction of overweight
will improve the coronary risk problem.”
“Avoidance of overweight would seem a desirable goal in the
general population if the appalling annual toll from disease
is to be substantially reduced.”

Trends in the prevalence of obesity among US children and adolescents by age and survey year
(National Health and Nutrition Examination Survey: 1971-1974, 1976-1980, 1988-1994, 1999-
2002 and 2005–2008)

Data derived from Health, United States, 2010: With Special Feature on Death and Dying. NCHS, 2011.

Age-adjusted prevalence of obesity in adults 20–74 years of age, by sex and survey year
(NHES: 1960–62; NHANES: 1971–74, 1976–80, 1988–94, 1999-2002 and 2005-08)

Data derived from Health, United States, 2010: With Special Feature on Death and Dying. NCHS, 2011.


Risk Factor Sum and Obesity
Framingham Study
3 (1971-74) and (1989-93)

2.4 (1971) (1989)
Risk Factor Sum

Risk factors accumulate with weight gain
1.8

1.2

0.6

0
Q1 Q2 Q3 Q4 Q5 Overall
Thin Obese
Risk variables include bottom quintile for HDL-C and top
quintiles for cholesterol, SBP, triglycerides and glucose Wilson PWF, & Kannel WB
Nutr Clin Care 1999; 1:44-50

Prevalence of students in grades 9–12 who met currently
recommended levels of PA
during the past 7 days by race/ethnicity and sex (YRBS: 2009).

Currently recommended levels is defined as activity that increased their heart rate and made them breathe hard some of the time for a total of at least
60 minutes per day on 5 of the 7 days preceding the survey. Source: MMWR Surveillance Summaries.1 NH indicates non-Hispanic.


Prevalence of regular leisure-time physical activity among
adults > 18 years of age
by race/ethnicity and sex (NHIS: 2009).

Source: Pleis et al, 2010. NH indicates non-Hispanic. Percents are age-adjusted. Regular leisure-time physical activity is defined as 3 or more sessions
per week of vigorous activity lasting at least 20 minutes or five or more sessions per week of light/moderate activity lasting at least 30 minutes.

Prevalence of students in grades 9 to 12 reporting current
cigarette use
by sex and race/ethnicity (YRBSS, 2009).

Source: MMWR Surveill Summ. 2010;59:1–142.NH indicates non-Hispanic.

Risk Assessment
Count major risk factors
• For patients with multiple (2+) risk
factors
– Perform 10-year risk assessment
• For patients with 0–1 risk factor
– 10 year risk assessment not required
– Most patients have 10-year risk <10%

ATP III Assessment of CHD Risk
For persons without known CHD, other forms of
atherosclerotic disease, or diabetes:
• Count the number of risk factors:
– Cigarette smoking
– Hypertension (BP ≥140/90 mmHg or on
antihypertensive medication)
– Low HDL cholesterol (<40 mg/dL)†
– Family history of premature CHD
CHD in male first degree relative <55 years
CHD in female first degree relative <65 years
– Age (men ≥45 years; women ≥55 years)

• Use Framingham scoring for persons with ≥ 2
risk factors* (or with metabolic syndrome) to
determine the absolute 10-year CHD risk.
(downloadable risk algorithms at
www.nhlbi.nih.gov)
Expert Panel on Detection, Evaluation, and Treatment of © 2001, Professional Postgraduate Services®
High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497. www.lipidhealth.org

ATP III Framingham Risk Scoring

Assessing CHD Risk in Men
Step 1: Age
Years Step 4: Systolic Blood Pressure Step 6: Adding Up the Points
Points Systolic BP Points Age
20-34 -9 Points
35-39 -4 (mm Hg) if Untreated if Total cholesterol
40-44 0 Treated
45-49 3 <120 0 0 HDL-cholesterol
50-54 6 120-129 0 1
55-59 8 130-139 1 2 Systolic blood pressure
60-64 10 140-159 1 2
65-69 11 ≥160 2 3 Step 7: CHD Risk
Smoking status
70-74 12 Point Total 10-Year Risk Point Total 10-
75-79 13 Year Risk Point total
Step 2: Total Cholesterol <0 <1% 11
8%
TC Points at Points at Points at Points at 0 1% 12
Points at 10%
(mg/dL) Age 20-39 Age 40-49 Age 50-59 Age 60-69
1 1% 13
Age 70-79
12%
<160 0 0 0 0
2 1% 14
0
16%
160-199 4 3 2 1
0 3 1% 15
20%
Step 3: HDL-Cholesterol
200-239 7 5 3 1
0 4 1% 16
HDL-C 25%
240-279 9 6 4 2
(mg/dL) Points Step 5: Smoking Status 5 2% ≥17
1
≥60
≥280 11 -1 8 ≥30%
5 Points at 3 Points at Points at Points at
1
50-59 0 Points at 6 2%
40-49 1 Age 20-39 Age 40-49 Age 50-597 Age 60-69 3%
Age 70-79 8 4%
<40 2
Nonsmoker 0 0 0 9 0 5%
Note: Risk estimates were derived from the experience of the Framingham Heart Study,
0 10 6%
a predominantly Caucasian population in Massachusetts, USA.
Smoker 8 5 3 1
1
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. © 2001, Professional Postgraduate Services®
www.lipidhealth.org
JAMA. 2001;285:2486-2497.


Assessing CHD Risk in Women
Step 4: Systolic Blood Pressure Step 6: Adding Up the Points
Step 1: Age
Systolic BP Points Age
Years Points
Points (mm Hg) if Untreated if Total cholesterol
20-34 -7 Treated
35-39 -3 <120 0 0 HDL-cholesterol
40-44 0 120-129 1 3
45-49 3 130-139 2 4 Systolic blood pressure
50-54 6 140-159 3 5
55-59 8 ≥160 4 6 Step 7: CHD Risk
Smoking status
60-64 10
Point Total 10-Year Risk Point Total 10-
65-69 12 Year Risk Point total
70-74 14
Step 75-79
2: Total Cholesterol <9 <1% 20
16
11%
TC Points at Points at Points at Points at 9 1% 21
Points at 14%
10 1% 22
Age 70-79
17%
<160 0 0 0 0
11 1% 23
0
22%
160-199 4 3 2 1
1 12 1% 24
27%
200-239 8 6 4 2
1 13 2% ≥25
HDL-C ≥30%
240-279 11 8 5 3
(mg/dL) Points Step 5: Smoking Status 14 2%
2
≥60
≥280 13 -1 10 7 Points at 4 Points at Points at15 Points at 3%
2
50-59 0 Points at 16 4%
40-49 1 Age 20-39 Age 40-49 Age 50-59 Age 60-69
17 5%
Age 70-79 18 6%
<40 2
Nonsmoker 0 0 0 19 0 8%
Note: Risk estimates were derived from the experience 0 the Framingham Heart Study,
of
a predominantly Caucasian population in Massachusetts, USA.
Smoker 9 7 4 2
1
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. © 2001, Professional Postgraduate Services®
www.lipidhealth.org
JAMA. 2001;285:2486-2497.


Step 1: Age
Men Women
Years Years
Points Points
20-34 -9 20-34 -7
35-39 -4 35-39 -3
40-44 0 40-44 0
45-49 3 45-49 3
50-54 6 50-54 6
55-59 8 55-59 8
60-64 10 60-64 10
65-69 11 65-69 12
70-74 12 70-74 14
75-79 13 75-79 16

Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. JAMA. 2001;285:2486-2497.
© 2001, Professional Postgraduate Services®
www.lipidhealth.org


Step 2: Total Cholesterol
Men TC Points at Points at Points at Points at
Points at
Age 70-79
<160 0 0 0 0
0
160-199 4 3 2 1
0
200-239 7 5 3 1
0
Women 240-279 9 6 4 2
TC1 Points at Points at Points at Points at
Points at
≥280 11 8 5 3
(mg/dL)
1 Age 20-39 Age 40-49 Age 50-59 Age 60-69 Age
70-79
<160 0 0 0 0
0
160-199 4 3 2 1
1
Note: TC and HDL-C values should 8 the average of at 6
200-239 be least two fasting 4 2
lipoprotein measurements.
1
240-279 11 8 5 3
2 © 2001, Professional Postgraduate Services®
Cholesterol in Adults. JAMA. 2001;285:2486-2497. www.lipidhealth.org
≥280 13 10 7 4


Men Women
HDL-C HDL-C
(mg/dL) (mg/dL)
Points Points
≥60 -1 ≥60 -1
50-59 0 50-59 0
40-49 1 40-49 1
<40 2 <40 2

Note: HDL-C and TC values should be the average of at least two
fasting lipoprotein measurements.

Cholesterol in Adults. JAMA. 2001;285:2486-2497. © 2001, Professional Postgraduate Services®
www.lipidhealth.org


Step 4: Systolic Blood Pressure
Men
Systolic BP Points Points
(mm Hg) if Untreated if Treated
<120 0 0
120-129 0 1
130-139 1 2
140-159 1 2
≥160 2 3

Women
Systolic BP Points
Points
(mm Hg) if Untreated if
Treated
<120 0 0
120-129 1 3
130-139 2 4
140-159 3 5
Note: The average of several BP measurements is needed for an accurate
≥160 4
measurement of baseline BP. If an individual is on antihypertensive treatment, 6
extra points are added.

Expert Panel on Detection, Evaluation, and Treatment of High Blood © 2001, Professional Postgraduate Services®
www.lipidhealth.org


MenStep 5: Smoking Status
Points at Points at Points at Points at
Points at
Age 20-39 Age 40-49 Age 50-59 Age 60-69 Age
70-79
Nonsmoker 0 0 0 0
0
Smoker 8 5 3 1
Women
1
Points at Points at Points at Points at
Points at
Age 20-39 Age 40-49 Age 50-59 Age 60-69 Age
70-79
Nonsmoker 0 0 0 0
0
Smoker 9 7 4 2
1
Note: Any cigarette smoking in the past month.

www.lipidhealth.org


Step 6: Adding Up the Points
(Sum From Steps 1–5)
Age
Total cholesterol
HDL-cholesterol
Systolic blood pressure
Smoking status
Point total

© 2001, Professional Postgraduate Services®
www.lipidhealth.org


Step 7: CHD Risk for Men
Year Risk
<0 <1% 11
8%
0 1% 12
10%
1 1% 13
12%
2 1% 14
16%
3 1% 15
20%
4 1% 16
25%
Note: Determine the 10-year absolute risk for2% CHD (MI and
5 hard ≥17
≥30%
coronary death) from point total.
6 2%
Cholesterol in Adults.7 3%
JAMA. 2001;285:2486-2497. © 2001, Professional Postgraduate Services®
8 4% www.lipidhealth.org

• Examination:
Presentation
– Height: 6 ft 2 in
– Weight: 220 lb (BMI 28
kg/m2)
– Waist circumference: 41
in
– BP: 150/88 mm Hg
– P: 64 bpm
– RR: 12 breaths/min
• Cardiopulmonary exam:
normal
• Laboratory results:
– TC: 220 mg/dL
– HDL-C: 36 mg/dL
– LDL-C: 140 mg/dL
– TG: 220 mg/dL
– FBS: 120 mg/dL

What is WJC’s 10-year absolute
risk
of fatal/nonfatal MI?
• A 12% absolute risk is derived from points
assigned in Framingham Risk Scoring to:
– Age: 6
– TC: 3
– HDL-C: 2
– SBP: 2
– Total: 13 points

In 1992 he exercised 14 minutes in a Bruce protocol exercise
stress test to 91% of his maximum predicted heart rate without
any abnormal ECG changes. He started on a statin in 2001.
But in Sept 2004, he needed urgent coronary bypass surgery.


Step 7: CHD Risk for Women
Year Risk
<9 <1% 20
11%
9 1% 21
14%
10 1% 22
17%
11 1% 23
22%
12 1% 24
27%
13 2% ≥25
≥30%
Note: Determine the 10-year absolute risk for2% CHD (MI and
14 hard
coronary death) from15 total.
point 3%
16 4%
17 5%
www.lipidhealth.org
18 6%

CHD Risk Equivalents
• Risk for major coronary events
equal to that in established CHD
• 10-year risk for hard CHD >20%
Hard CHD = myocardial infarction + coronary
death

Diabetes as a CHD Risk
Equivalent
• 10-year risk for CHD ≅ 20%
• High mortality with established CHD
– High mortality with acute MI
– High mortality post acute MI

CHD Risk Equivalents
• Other clinical forms of
atherosclerotic disease (peripheral
arterial disease, abdominal aortic
aneurysm, and symptomatic carotid
artery disease)
• Diabetes
• Multiple risk factors that confer a 10-
year risk for CHD >20%

Framingham 10-year Total CVD
Risk Algorithm (D’Agostino et al
2008)

International Comparisons in
CVD Morbidity and Mortality
• CVD accounts for 25-45% of deaths
among different countries
• CVD death rates (per 100,000)
range from 1310 in Russia to 201 in
Japan (6.5 fold difference) in men
and from 581 in Russia to 84 in
France (7-fold difference)
• USA ranks 16th for both men (413)
and women (201)

Secular Trends in CHD and
Stroke Mortality
• From 1985-1992, greatest annual
decline (6-7%) in CHD seen in Israel
among men and France among
women, USA intermediate (4%),
increases in Poland and Romania.
• Stroke death rates declined most in
Australia, Italy, and France (8-9%),
USA about 3%.

Age-Adjusted Death Rates for Coronary Heart Disease by Country and Sex,
Ages 35-74, 1999

•Age-Adjusted to European Standard
•Data for 1999 unless noted
Source: NHLBI 2002 Chart Book on Cardiovascular, Lung, and Blood Diseases

Age-Adjusted Death Rates for Stroke by Country and Sex, Ages 35-74, 1999

•Data for 1999 unless noted

Change in Age-Adjusted Death Rates for Coronary Heart Disease by Country and
Sex, Ages 35-74, 1990-1999

Men

Women

•Latest data year note in parentheses

Change in Age-Adjusted Death Rates for Stroke by Country and Sex, Ages 35-74,
1990-1999

Men

Women

•Latest data year note in parentheses

Migrant Studies

• Ni-Hon-San Study showed
Japanese living in Japan to have
the lowest cholesterol levels and
lowest rates of CHD, those living in
Hawaii to have intermediate rates
for both, and those living in San
Francisco to have the highest
cholesterol levels and CHD
incidence

Pyramid of Risk
(Werner et al. Canadian Journal of
Cardiology 1998; 14(Suppl) B:3B-10B)

Approaches to Primary and
Secondary Prevention of
CVD
• Primary prevention involves prevention
of onset of disease in persons without
symptoms.
• Primordial prevention involves the
prevention of risk factors causative o the
disease, thereby reducing the likelihood
of development of the disease.
• Secondary prevention refers to the
prevention of death or recurrence of
disease in those who are already
symptomatic

Risk Factor Concepts in
Primary Prevention
• Nonmodifiable risk factors include age,
sexc, race, and family history of CVD,
which can identify high-risk populations
• Behavioral risk factors include sedentary
lifestyle, unhealthful diet, heavy alcohol
or cigarette consumption.
• Physiological risk factors include
hypertension, obesity, lipid problems,
and diabetes, which may be a
consequence of behavioral risk factors.

Population vs. High-Risk
Approach
• Risk factors, such as cholesterol or blood
pressure, have a wide bell-shaped distribution,
often with a “tail” of high values.
• The “high-risk approach” involves
identification and intensive treatment of those
at the high end of the “tail”, often at greatest
risk of CVD, reducing levels to “normal”.
• But most cases of CVD do not occur among the
highest levels of a given risk factor, and in fact,
occur among those in the “average” risk group.
• Significant reduction in the population burden
of CVD can occur only from a “population
approach” shifting the entire population
distribution to lower levels.

Expected Shifts in Cholesterol Distribution
from High-Risk, Population, and
Combined Approaches

Population and Community-
Wide CVD Risk Reduction
Approaches
• Populations with high rates of CVD are those with
Western lifestyles of high-fat diets, physical
inactivity, and tobacco use.
• Targets of a population-wide approach must be
these behaviors causative of the physiologic risk
factors or directly causative of CVD.
• Requires public health services such as
surveillance (e.g.,BFRSS), education (AHA,
NCEP), organizational partnerships (Singapore
Declaration), and legislation/policy (Anti-Tobacco
policies)
• Activities in a variety of community settings:
schools, worksites, churches, healthcare
facilities, entire communities

A conceptual framework for public
health practice in CVD prevention.
(From Pearson et al., J Public Health. 2001; 29:69 –78)

Communitywide CVD
Prevention Programs
• Stanford 3-Community Study (1972-75)
showed mass media vs. no intervention in
high-risk residents to result in 23% reduction
in CHD risk score
• North Karelia (1972-) showed public education
campaign to reduce smoking, fat
consumption, blood pressure, and cholesterol
• Stanford 5-City Project (1980-86) showed
reductions in smoking, cholesterol, BP, and
CHD risk
• Minnesota Heart Health Program (1980-88)
showed some increases in physical activity
and in women reductions in smoking

Materials Developed for US
Community Intervention
Trials
• Mass media, brochures and direct mail
• Events and contests
• Screenings
• Group and direct education
• School programs and worksite
interventions
• Physician and medical setting programs
• Grocery store and restaurant projects
• Church interventions
• Policies

Individual and High-Risk
Approaches
• Primary Prevention Guidelines (1995) and
Secondary Prevention Guidelines (Revised 2001)
released by the American Heart Association
provide advice regarding risk factor assessment,
lifestyle modification, and pharmacologic
interventions for specific risk factors
• Barriers exist in the community and healthcare
setting that prevent efficient risk reduction
• Surveys of CVD prevention-related services show
disappointing results regarding cholesterol-
lowering therapy, smoking cessation, and other
measures of risk reduction

Cvd definitions and statistics jan 2012

More Related Content

Similar to Cvd definitions and statistics jan 2012 (20)

More from nahomyitbarek (20)

Cvd definitions and statistics jan 2012

Editor's Notes